Association of tumor burden with the eligibility of upfront therapy in patients with castration-naive prostate cancer: A multicenter retrospective study.
Hiromichi Iwamura(Hirosaki University), Chikara Οhyama(Hirosaki University), Tomonori Habuchi(Akita University), Akihiro Ito(Tohoku University), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Norihiko Tsuchiya(Yamagata University), Shintaro Narita(Akita University), Fumitada Saito, Koji Mitsuzuka(Pacific Northwest Diabetes Research Institute), Senji Hoshi, Yoichi Arai(Japan Atomic Energy Agency), Toshihiko Sakurai(Sojo University), Shingo Hatakeyama(Hirosaki University), Toshiaki Kawaguchi(Aomori Prefectural Central Hospital)
Cited by 0
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial
|Journal of Clinical Oncology|2013|253